Clinical trials: ESCC
Esophageal Squamous Carcinoma
Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC
This is a single-arm, exploratory clinical study.
- Trial name
- NCT07490002
- Testing
- Iparomlimab and Tuvonralimab+Lenvatinib + Cisplatin/Carboplatin + Nab-paclitaxel
- Volunteers
- 33 people
- Sponsor
- Changhai Hospital
Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
The goal of this interventional study is to compare the safety and efficacy of neoadjuvant immunotherapy plus chemotherapy and anlotinib versus immunotherapy combined with concurrent chemoradiotherapy in the treatment of locally…
- Trial name
- NCT06354530
- Testing
- anlotinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Army Medical Center of PLA
Resectable Esophageal Squamous Cell Carcinoma
Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC
This study is an open-label, prospective, cohort clinical study to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in…
- Trial name
- NCT06475196
- Testing
- Sintilimab (PD-1 inhibitor)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tang-Du Hospital
Esophageal Squamous Cell Carcinoma by AJCC V8 Stage
Immunotherapy After Radiotherapy in Elderly ESCC
The incidence and mortality of esophageal squamous cell carcinoma are at the forefront in China.Most part of patients are elderly.
- Trial name
- TREE (NCT05791136)
- Testing
- Radiotherapy, Toripalimab
- Volunteers
- 30 people
- Sponsor
- The Central Hospital of Lishui City
Esophageal Cancer
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
To assess the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (with symptomatic dysphagia or oligometastatic…
- Trial name
- NCT06464614
- Testing
- Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC)
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Squamous Cell Carcinoma Metastatic
A Study of SBRT for OligoMetastatic ESCC
The aim of this phase II trial is to assess progress-free survival, local control, overall survival, safety and tolerability of SBRT to treat patients with oligometastases in esophageal squamous cell carcinoma.
- Trial name
- NCT03000816
- Testing
- SBRT
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Fudan University
ESCC
Adebrelimab Neoadjuvant Treatment for Resectable ESCC
This is a prospective, phase II, exploratory clinical trial. The study aims to evaluate the efficacy and safety of in combination adebrelimab with nimotuzumab and chemotherapy as neoadjuvant therapy in patients with resectable…
- Trial name
- NCT07388095
- Testing
- Adebrelimab (PD-L1 inhibitor)
- Volunteers
- 22 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Carcinoma, HER-2 Protein Overexpression
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC
This is a single-arm, exploratory clinical study.
- Trial name
- NCT06055153
- Testing
- RC48+PD-1+platinum-based
- Volunteers
- 20 people
- Sponsor
- Changhai Hospital
P53 Mutation in Esophageal Cancer
ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance
Collect 300 esophageal cancer tissue specimens, including cancer tissue and serum, from a biological sample bank. Collect clinical information on esophageal cancer, including gender, age, time of diagnosis, time of death…
- Trial name
- NCT07722819
- Testing
- No intervention
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ling Zhiqiang
Esophageal Squamous Cell Carcinoma
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
- Trial name
- ESCC (NCT06601309)
- Testing
- Serplulimab, Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy), Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Medical University Union Hospital
Esophageal Squamous Cell Carcinoma, Ivonescimab
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant
- Trial name
- NCT07385001
- Testing
- AK112, AK112 + Neoadjuvant chemotherapy
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tang-Du Hospital
Esophageal Squamous Cell Carcinoma, Stage III
Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)
The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin followed by Da Vinci robot radical surgery for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT04389177
- Testing
- Pembrolizumab Injection [Keytruda]
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Esophageal Squamous Cell Carcinoma
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.
- Trial name
- NCT05142709
- Testing
- Anti-PD-1 Immune Checkpoint Inhibitors
- Where
- 23 sites in China
- Volunteers
- 1,197 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
This is a single arm, multi-center Phase II Study. This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of Chemoradiationtherapy combined with…
- Trial name
- NCT05490719
- Testing
- QL1706
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
The goal of this clinical trial is to evaluate the efficacy and safety of sintilimab as adjuvant therapy in node-positive esophageal squamous cell carcinoma after radical surgery without neoadjuvant therapy.
- Trial name
- NCT06190639
- Testing
- sintilimab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
The goal of this phase II clinical trial is to explore the efficacy and safety of anti-PD1 combined with stereotactic body radiation therapy (SBRT) for patients with oligometastatic esophageal squamous cell carcinoma.
- Trial name
- NCT05626569
- Testing
- PD-1 combined with SBRT
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma
AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
This is a two-arm, open, multicenter clinical study to evaluate the efficacy and safety of AK104 alone or in combination with cisplatin and paclitaxel in the treatment of advanced esophageal squamous carcinoma without systemic…
- Conditions
- Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT05522894
- Testing
- AK104, Cisplatin, Paclitaxel
- Volunteers
- 80 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophagus Cancer, Stage III
GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC)
Caffeic acid can target inhibit GASC1 (gene amplified in squamous cell carcinoma 1, also known as KDM4C and JMJD2C) expression and GASC1 is confirmed to be a new oncogene in several cancers including esophageal cancer.
- Trial name
- GiCAEC (NCT04648917)
- Testing
- Caffeic acid
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC)
This study aims to evaluate the efficacy and safety of induction Adebrelimab (anti-PD-L1 antibody) combined with chemotherapy, then guided by PET-CT or RECIST1.1 assessment to change the following chemoradiotherapy regiment for…
- Trial name
- NCT07112833
- Testing
- Induction stage：Adebrelimab+TC；Treatment stage: TC/PF+ radiation therapy；Maintenance stage: Adebrelimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Hebei Medical University Fourth Hospital
Carcinoma, Squamous Cell
Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols
Evidence from laboratory studies suggests that aspirin and tea polyphenols may have an antineoplastic effect in esophageal squamous cell carcinoma (ESCC).
- Trial name
- CREAT (NCT01496521)
- Testing
- Aspirin, Tea Polyphenols
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital